BioVersys
Manufacturing · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
C/o Technologiepark Hochbergerstrasse 60...Phone Number
+41 615515120Website
www.bioversys.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About BioVersys
BioVersys is a Swiss pharmaceutical company dedicated to combating antimicrobial resistance (AMR) and improving patient outcomes through innovative research and development. The company focuses on creating small molecules that target drug-resistant infections, including tuberculosis and serious hospital infections. With a rich pipeline of novel therapies, BioVersys aims to address unmet medical needs and tackle the growing threat of antibiotic-resistant germs. Their mission is to save lives and enhance global healthcare systems in the face of this silent pandemic.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioVersys your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if BioVersys is spiking on competitors!
Click to see if BioVersys had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if BioVersys has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at BioVersys
BioVersys, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when BioVersys launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once BioVersys has new funding data
Earning: See what the market has to say on BioVersys recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined BioVersys as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
BioVersys is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioVersys is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioVersys.
BioVersys financials insights
Gather financial insights about BioVersys, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$5M
2020
Series B
$20.9M
2024
Series C
$47.5M
BioVersys Tech Stack
A closer look at the technologies used by BioVersys
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals
Partnership
Partnership, Business Development, Intellectual Property, Medical Research, Pharmaceuticals, Healthcare Technology
Project
Laboratory Operations, Medical Research, Clinical Operations
Hiring Plans
BioVersys has more open roles in Medical & Health than it has had at any time in the past 12 months. Areas of expertise include: Anesthesiology, Infectious Diseases, Early Clinical Development, Clinical System Operations, Medical Monitoring, Internal Medicine, and Biotechnology.
Hiring Plans
Hiring Plans
Hiring Plans
BioVersys News & Media
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
Ad hoc announcement pursuant to Art. 53 LR Ad hoc announcement pursuant to Art. 53 LRBioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026
BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) -- BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today its participation in the 36th Congress of the European Society of Clinical Microbiology & Infectious Diseases (ESCMID Global 2026), where it will present the latest preclinical data on its leData Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE)
BASEL, Switzerland, April 13, 2026 (GLOBE NEWSWIRE) -- BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today, the publication of pre-clinical data in the prestigious journal of Nature Communications, for its innovative anti-tuberculosis combination AlpE.1
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioVersys
Sign Up For FreeTo access detailed company insights
BioVersys is a Swiss pharmaceutical company dedicated to combating antimicrobial resistance (AMR) and improving patient outcomes through innovative research and development. The company focuses on creating small molecules that target drug-resistant infections, including tuberculosis and serious hospital infections. With a rich pipeline of novel the... Read More
